A groundbreaking trial called PURPOSE 1 has yielded remarkable results, offering a promising alternative to daily pills for HIV prevention.
The trial, sponsored by Gilead Sciences, involved 5,300 cisgender women in South Africa and Uganda, with 2,134 receiving a twice-yearly injection of the drug lenacapavir. None of the women who received the injection contracted HIV, a significant achievement.
The focus on women in sub-Saharan Africa is crucial, as the region bears the brunt of the HIV epidemic, with 60% of global cases despite having only 10% of the world’s population. Alarmingly, 4,000 teen girls and young women in Africa are newly infected every week.
While oral PrEP has shown high effectiveness in trials, real-world effectiveness can be significantly lower, with one study showing a mere 26% effectiveness in men under 30. Lenacapavir, given every six months, could bridge this gap and provide a more practical solution.
Although lenacapavir has been FDA-approved (Food and Drug Administration) for multi-drug resistant HIV treatment since 2022, PURPOSE 1 is the first trial to test its efficacy in HIV prevention. The initiative aims to end the HIV epidemic by 2030. However, cost remains a significant challenge, with lenacapavir’s current price in the US being $42,250 per new patient, making access difficult in low-income regions.
The early success of lenacapavir as a twice-yearly injection for HIV prevention offers hope for better global health. Continued efforts and collaborations are essential to make this innovation accessible to all who need it.
